Posted by Jedi on January 1, 2006, at 4:03:01
In reply to Provigil as mood enhancer?, posted by blueberry on December 31, 2005, at 17:41:06
> I am aware provigil is good for staying awake, staying alert, and being active. But what about its effects on depression?
...Hi,
I haven't used modafinil so I have no first hand knowledge. There is some current research that suggests efficacy in using modafinil as an augmentation stategy for depression.
Jedi
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16208839&query_hl=1&itool=pubmed_docsum
Nord J Psychiatry. 2005;59(3):173-8.
Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92).Rasmussen NA, Schroder P, Olsen LR, Brodsgaard M, Unden M, Bech P.
Psychiatric Research Unit, Frederiksborg General Hospital, Dyrehavevej, Hillerod, Denmark.Treatment-resistant depression, i.e. partial or non response to antidepressants in spite of various treatment attempts with optimized doses and combinations, is rather common. With residual symptoms such as tiredness, anhedonia and concentration disturbances, the treatment strategy has often been to use monoamino-oxidase inhibitors (MAOIs). Their use, however, is limited due to interaction problems. Modafinil is recently developed wake-promoting drug with only minor side-effects. Pilot studies indicate that it appears to have an augmentation effect in treatment-resistant depression. This open-label study performed in the private psychiatric practice setting is the first to make a comprehensive evaluation of the target patient profile based on patient-reported symptoms. Modafinil in doses of 100-400 mg was administered as augmentation to ongoing antidepressant therapy in patients with partial response and suffering from hypersomnia. The total number of patients was 21 and 43% of these were responders (i.e. had a score reduction of >50% on the Major Depression Inventory (MDI) as well as remitters, i.e. the remission rate was 43%. At endpoint, the responders had psychological distress scores on the Symptom Checklist (SCL-92) on the level of the general Danish population. Baseline characteristics for responders were lower scores on depression, hostility, anxiety, somatization, obsession and psychoticism. Modafinil thus appears to be an appropriate augmentation to antidepressant treatment, leading to a remission rate of 43%. However, the results from this open-label study need ot be confirmed in a placebo-controlled trial.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15096082&query_hl=5&itool=pubmed_docsum
J Clin Psychiatry. 2004 Mar;65(3):414-20.
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15669893&query_hl=5&itool=pubmed_docsum
J Clin Psychiatry. 2005 Jan;66(1):85-93.
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
poster:Jedi
thread:593788
URL: http://www.dr-bob.org/babble/20051231/msgs/593893.html